Stockreport

Aprea Therapeutics Reports Third quarter 2025 Financial Results and Provides a Clinical Update [Yahoo! Finance]

Aprea Therapeutics, Inc.  (APRE) 
PDF at Dose Level 6 (100 mg once daily) achieved stable disease, per RECIST v1.1, in heavily pretreated gastrointestinal and gynecologic malignancies ATRN-119 (ATR kinase [Read more]